Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a, Open-label Study of Visilizumab in Patients With Moderate-to-Severe Inflammatory, Nonstricturing, Nonpenetrating Forms of Crohn's Disease

NCT00267722 is registered in ClinicalTrials.gov with Facet Biotech as lead sponsor.

NCT NCT00267722
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00267722 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a, Open-label Study of Visilizumab in Patients With Moderate-to-Severe Inflammatory, Nonstricturing, Nonpenetrating Forms of Crohn's Disease
Lead sponsor
Facet Biotech
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2005
Completion date
December 31, 2006
Enrollment
18
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

crohn's disease